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Introduction
Acute-on-chronic liver failure (ACLF) is a fre-
quent syndrome in patients with cirrhosis that is 
characterized by local and systemic inflammation, 
impairment in cardiovascular function, mitochon-
drial dysfunction, and increased apoptosis. 
Clinically, it is associated with organ failure and 
high (22–74%) 28-day mortality.1–4 Unfortunately, 
no specific therapies exist, and current treatment 
is limited to that of associated complications and 
organ support.
Artificial liver support systems (ALS) that aim to 
provide temporary support of liver and kidney 
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Abstract
Background: Acute-on-chronic liver failure (ACLF) is a common complication of cirrhosis 
characterized by single or multiple organ failures and high short-term mortality. Treatment 
of ACLF consists of standard medical care (SMC) and organ(s) support. Whether the efficacy 
of artificial liver support (ALS) depends on the severity of ACLF or on the intensity of this 
treatment, or both, is unclear. This study aimed to further assess these issues.
Methods: We performed an individual patient data meta-analysis assessing the efficacy 
of Molecular Adsorbent Recirculating System (MARS) in ACLF patients enrolled in prior 
randomized control trials (RCTs). The meta-analysis was designed to assess the effect of 
patient severity (ACLF grade) and treatment intensity [low-intensity therapy (LIT), SMC alone 
or SMC plus ⩽ 4 MARS sessions, high-intensity therapy (HIT), SMC plus > 4 MARS sessions] 
on mortality.
Results: Three RCTs suitable for the meta-analysis (n = 285, ACLF patients = 165) were 
identified in a systematic review. SMC plus MARS (irrespective of the number of sessions) 
did not improve survival compared with SMC alone, neither in the complete population nor in 
the ACLF patients. Survival, however, was significantly improved in the subgroup of patients 
receiving HIT both in the entire cohort (10-day survival: 98.6% versus 82.8%, p = 0.001; 30-day 
survival: 73.9% versus 64.3%, p = 0.032) and within the ACLF patients (10-day survival: 97.8% 
versus 78.6%, p = 0.001; 30-day survival: 73.3% versus 58.5%, p = 0.041). Remarkably, HIT 
increased survival independently of ACLF grade. Independent predictors of survival were age, 
Model for End-Stage Liver Disease (MELD), ACLF grade, number of MARS sessions received, 
and intensity of MARS therapy.
Conclusion: HIT with albumin dialysis may improve survival in patients with ACLF. Appropriate 
treatment schedules should be determined in future clinical trials.
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function have been evaluated in patients with 
ACLF.5 Several randomized controlled trials 
(RCTs) evaluating the Molecular Adsorbent 
Recirculating System (MARS), which has been 
the most studied ALS device, have shown 
improvements in biochemical parameters and 
hepatic encephalopathy (HE) following MARS, 
but its effect on survival remains unclear.6–9 In 
this regard, several meta-analyses have shown dis-
crepant results.10–12 Importantly, the potential 
time-dependent effect of MARS on survival and 
the identification of robust predictors of response 
could not be assessed in those meta-analyses, as 
they were not based on individual data. No prog-
nostic stratification of patients was used either,13,14 
as the trials were performed before the new char-
acterization of the ACLF syndrome.1
In this study, we performed a meta-analysis using 
individual patient data to overcome these limita-
tions. Our aims were: To compare the effect of 
MARS plus standard medical care (SMC) versus 
SMC alone on survival; to identify predictors of 
mortality, including the severity of ACLF and the 
intensity of MARS therapy; and to evaluate the 
safety profile of MARS therapy.
Methods
Study selection
The current meta-analysis was designed to pool 
individual patient data from RCTs comparing 
MARS-SMC versus SMC alone in cirrhotic 
patients with acute decompensations. A compre-
hensive search of the literature (PubMed, 
EMBASE, CT registries, and the Cochrane 
Library) was performed according to the follow-
ing strategy [‘ACLF’ OR ‘acute-on-chronic liver 
failure (Mesh)’] and (‘MARS’ OR ‘albumin dial-
ysis’). Identification of trials, the definition of 
outcomes, data processing, and statistical analysis 
was carried out following a prespecified plan. 
RCTs considered for evaluation were analyzed 
independently by two authors who decided which 
trials were eligible according to the following cri-
teria: They were published as full articles; a ran-
dom allocation of patients with an acute 
decompensation of cirrhosis received either ALS 
with the MARS system or SMC; and data of sur-
vival as a primary or secondary outcome.
Four RCTs fulfilled the predefined inclusion cri-
teria (Figure 1(a)). We had access to the 
individual patient data directly from the original 
case report form (CRF) in three trials.7–9 It was 
not possible to obtain accurate individual infor-
mation from the fourth trial.6 The number of 
patients included in the meta-analysis represented 
over 90% of the randomized patients in the four 
studies. Table 1 summarizes the main character-
istics of the three RCTs selected.
Only one of the three studies included in the 
meta-analysis was originally designed to find dif-
ferences in survival.9 In the remaining two studies 
the primary endpoint was the resolution of HE 
and a sustained reduction of bilirubin.7,8 The 
30-day survival was recorded in the three studies, 
and the 90-day survival was also recorded in one 
of them.9
The meta-analysis
Duration and number of MARS sessions were 
prespecified in all RCTs. Patients received up to 
10 sessions of 6–8 h in 2 studies, while the maxi-
mum of sessions allowed in the third study was 5. 
As per the protocol of RCT, MARS therapy was 
discontinued when patients reached the endpoint 
of the study, presented sustained improvement or 
underwent liver transplantation.
The individual patient data was extracted directly 
from the CRF, pooled and verified by three of the 
authors. The database was recorded and checked 
for completeness and internal consistency.
The obtained information was analyzed to reclas-
sify the patients according to the ACLF-
CANONIC definition (Supplementary materials). 
Because several important data for the diagnosis 
or stratification of ACLF was absent or insuffi-
ciently described in the CRFs, the following 
assumptions had to be considered:
(1) In one RCT,7 prothrombin activity instead 
of INR was available. Conversion of pro-
thrombin time was performed to calculate 
INR.
(2) If information about the fraction of 
inspired oxygen (FiO2) was not recorded 
in the CRF, a value of 0.21 was assumed.
(3) Precise information on vasoactive drug use 
could not be retrieved from the CRFs in 
many patients. Therefore 2 points was the 
maximum chronic liver failure organ failure 
(CLIF-C OF) score assigned to circulatory 
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failure. This assumption was taken because, 
according to the CANONIC study, it would 
rarely affect ACLF grading, since circula-
tory failure in patients with ACLF grades 1 
and 2 is extraordinarily infrequent.
To explore the impact of the intensity of MARS 
therapy on survival, a post hoc analysis was carried 
out. Patients were combined into a single cohort 
and restratified into two different groups accord-
ing to the number of MARS sessions delivered, 
LIT, and HIT. A cutoff of four treatment ses-
sions (the median number of sessions in the 
MARS treated patients) was selected for stratifi-
cation. Consequently, the HIT group included 
patients receiving five or more MARS sessions, 
whereas the LIT group included patients allo-
cated to SMC and patients receiving four or fewer 
MARS sessions.
Outcomes
The primary outcome was 30-day survival. In 
addition, 10-day survival was considered as an 
estimation of the survival within the period of 
active organ support. Data for patients who were 
transplanted before reaching the 30-day follow up 
were censored as of the date of transplantation.
Secondary outcomes were changes in bilirubin, 
creatinine, and severity of HE 4 days after enrol-
ment. The 4-day period was selected because it is 
included within the most suitable period (3–7 
days after enrolment) for the prediction of prog-
nosis in ACLF patients.14
Assessment of adverse events
Two out of three RCTs included in the meta-
analysis had a predefined system for notification 
and monitoring of adverse events (AEs). One 
investigator, blinded to the group of interven-
tions, reviewed the original CRFs to classify AEs 
according to their severity and type.
Comparison with the CANONIC cohort
A comparison between the patients with ACLF 
included in the meta-analysis and the 303 patients 
included in the CANONIC study with ACLF at 
enrolment (including clinical characteristics, and 
10-day and 30-day survival) was performed.
Figure 1. (a) Searching strategy. * Studies were excluded because of the absence of a control group, or 
random allocation, or because the study included patients with acute liver failure. (b)Number of MARS 
sessions received in LIT (⩽4 MARS sessions) and HIT groups (⩾5 MARS sessions).
HIT, high-intensity therapy; LIT, low-intensity therapy; MARS, molecular adsorbent recirculating system.
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Statistical analysis
Continuous variables are described by mean 
(standard deviation), the normality of continuous 
variables was evaluated using a Kolmogorov–
Smirnov test. Paired and unpaired Student’s t 
test, one-way analysis of variance (ANOVA) and 
the chi-squared test (χ2) were used as appropri-
ate. The Kaplan–Meier method and the Breslow 
test were used to evaluate survival differences.
Univariate and multivariate Cox proportional 
hazard models were used to identify risk factors 
for survival. The variables with a p value < 0.1 
were included in the multivariate models. As we 
specifically aimed to evaluate the impact of inten-
sity of therapy and the severity of ACLF, we 
developed the following modeling strategy. First, 
we performed a model including the MELD score 
as a covariate that estimates the severity of the 
liver disease. Then, we developed a second model 
in the population in which the presence and sever-
ity of ACLF could be obtained. In this model, 
ACLF grade was included as the covariate that 
specifically estimates severity. Finally, we devel-
oped a model including the ACLF grade and the 
number of MARS sessions.
A logistic regression model was also fitted to esti-
mate the probability of 30-day mortality in 
patients receiving LIT and HIT at different levels 
of severity, as measured by the CLIF-C ACLF 
score.13
Statistical analyses were performed using SPSS 
version 21 (SPSS, Chicago, IL, USA). All p val-
ues were two-tailed. All of the results are reported 
as per protocol because the intention to treat 
analysis was not possible in two of the three stud-
ies. This meta-analysis was conducted in accord-
ance with the PRISMA guidelines and was 
exempted from ethical evaluation by the local 
institutional review board.
Results
Patients
The final database consisted of 285 patients, 147 
allocated to MARS treatment and 138 to SMC. 
Evaluation of the presence and grade of ACLF 
was possible in 201 patients (70.5% of the total 
sample). Among the patients in which ACLF 
could be evaluated, 36 patients (17.9%) had no 
ACLF at enrolment, 49 patients (24.4%) 
presented ACLF 1, 53 patients (26.4%) had 
ACLF 2, and 63 patients (31.3%) had ACLF 3. 
Therefore, ACLF was present in 165 patients 
(82.1%).
In total 13 of the patients included in the meta-
analysis (4.6%) underwent liver transplantation 
within a 30-day period (SMC = 5 patients versus 
MARS = 8 patients; p = 0.477. LIT = 10 patients 
versus HIT = 3 patients; p = 0.563).
Overall, there were no differences between groups 
regarding the etiology and severity of the liver dis-
ease, presence, and severity of ACLF, or the 
number of organ failures (Table 2). Additionally, 
there were no differences between the LIT and 
the HIT groups, apart from the LIT group having 
a higher proportion of patients with cerebral fail-
ure (41.9% versus 25.3%; p = 0.013) and a lower 
proportion of patients with liver failure (77.6% 
versus 89.0%; p = 0.034) (Table 2). The severity 
of ACLF was also similar.
Compared with the CANONIC study 
(Supplementary Table 1), the patients included in 
the present meta-analysis were younger (p = 0.001), 
had a higher proportion of alcoholic etiology 
(p = 0.011), presented more frequent liver, brain 
and respiratory failures (p = 0.001) and less kidney 
(p = 0.022) and coagulation (p = 0.003) failures, 
and had higher MELD and serum bilirubin 
(p = 0.001). Of note, patients in the meta-analysis 
also presented a lower prevalence of ACLF 1, a 
higher prevalence of ACLF 3 (p < 0.001), and a 
higher grade of systemic inflammation, as esti-
mated by the  white blood cells (WBC) (p = 0.001).
Effect of MARS and influence of treatment 
intensity on survival
The effect of MARS on survival was evaluated 
before and after the reclassification of the patients 
according to treatment intensity. For the latter, 
212 patients were classified in the LIT group (138 
patients treated with SMC and 74 with SMC plus 
⩽4 sessions of MARS), and 73 in the HIT group 
(Figure 1(b)). When treatment intensity was not 
taken into account, the probability of survival was 
similar in patients treated with or without MARS 
[(10 day survival: 87.6% versus 86.1%; 30- day 
survival: 68.0% versus 65.4%); see Figure 2(a)]. 
However, reclassification by treatment intensity 
indicated that 30-day survival was higher in the 
HIT group than in the LIT group [(73.9% versus 
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Table 2. Characteristics of patients included in the meta-analysis. The first number in each column denotes the total number in 
which the evaluated parameter was available.
SMC group MARS group p value Low-intensity High-intensity p value
 (n = 138) (n = 147) (n = 212) (n = 73)
Background and 
exploratory data
 
Age 138 51.5 (11.4) 147 51.2 (10.31) 0.780 212 50.7 (11.3) 73 50.9 (10.14) 0.921
Male sex (%) 138 64.5 147 63.9 0.923 212 64.5 73 63.9 0.805
Alcoholic cirrhosis (%) 138 76.1 147 74.1 0.980 212 73.1 73 80.8 0.239
Mean arterial pressure 
(mmHg)
133 81.6 (15.5) 141 79.8 (14.7) 0.331 202 81.3 (15.8) 72 78.8 (12.8) 0.236
ACLF grade 94 107 0.391 149 52 0.466
 No ACLF 21.3 15.0 19.5 13.5  
 ACLF 1 24.5 24.3 22.1 30.8  
 ACLF 2 21.3 30.8 25.5 28.8  
 ACLF 3 33.0 29.9 32.9 26.9  
Type and number of 
organ failures
 
 Liver (%) 138 79.0 143 82.1 0.512 210 77.6 73 89.0 0.034
 Kidney (%) 138 24.6 143 21.7 0.678 207 31.4 70 22,8 0.174
 Cerebral (%) 138 37.7 143 37.8 0.984 210 41.9 71 25.3 0.013
 Coagulation (%) 131 11.5 139 7.9 0.325 202 11.4 68 4.4 0.092
 Circulation (%) 133 13.6 141 17.3 0.416 202 17.8 72 22.2 0.414
 Respiration (%) 102 17.3 126 24.6 0.179 169 21.3 66 21.3 0.999
Number of Organ 
failures
94 2.1 (1.3) 107 2.0 (1.1) 0.832 149 2.1 (1.3) 52 1.9 (1.1) 0.527
Laboratory data  
Bilirubin (mg/dl) 133 25.2 (13.5) 145 25.4 (13.5) 0.858 210 24.4 (13.6) 73 27.8 (12.8) 0.060
INR 131 1.9 (0.6) 139 1.9 (0.6) 0.860 202 1.9 (0.7) 68 1.8 (0.5) 0.388
Creatinine (mg/dl) 134 2.2 (1.8) 143 2.2 (1.8) 0.731 207 2.2 (1.8) 70 2.2 (1.9) 0.948
Na (mEq/l) 137 133.4 (10.6) 144 134.8 (9.7) 0.244 210 134.2 (10.1) 71 134.0 (10.4) 0.898
Leukocytes (×103/µl) 137 14.6 (10.4) 146 13.9 (8.2) 0.505 211 13.9 (9.5) 72 15.2 (8.8) 0.302
Platelets (×103/µl) 137 123.4 (89.7) 145 119.2 (70.2) 0.670 210 120.6 (84.3) 72 123.2 (67.1) 0.810
 MELD score 127 30.2 (8.2) 134 30.8 (7.6) 0.581 195 30.4 (8.2) 66 31.0 (7.0) 0.582
Number of MARS 
sessions
138 0 (0.0) 147 5.1 (3.1) 0.001 212 1.1 (1.5) 73 7.8 (2.1) 0.001
INR, international normalized ration; MARS, Molecular Adsorbent Recirculating System; MELD, Model for End-Stage Liver Disease; SMC, standard 
medical care.
R Bañares, L Ibáñez-Samaniego et al.
journals.sagepub.com/home/tag 7
64.2% p = 0.032); see Figure 2(b)). To ascertain 
whether the relationship between treatment inten-
sity and survival was due to the potential influence 
of early mortality on the number of MARS ses-
sions received rather than to a real beneficial effect 
of MARS, we performed a Cox regression analysis 
including the number of MARS sessions delivered 
as a continuous variable (Supplementary Table 2 
model 3). Remarkably, the number of MARS ses-
sions was also independently associated with sur-
vival [HR 0.90 (CI 95% 0.83–0.98); p = 0.021]. 
Additionally, the chronological relationship 
between MARS discontinuation and death was 
evaluated in all patients included in the LIT 
group. MARS discontinuation that occurred 
within 24 h prior to death was considered death-
related (5 out of 28 patients). In the remaining 
patients, discontinuation occurred 2 days (two 
patients), 3 days (one patient), and 5 or more days 
(20 patients) before death, suggesting that MARS 
discontinuation might have been related to death 
in only a minority of patients. Furthermore, the 
probability of 10-day survival after excluding from 
the analysis the five patients with MARS discon-
tinuation within 24 h prior to death remained 
higher in the HIT group (98.6% versus 81.8%, 
p = 0.012; Supplementary Figure 1). MARS ther-
apy was also associated with improvements of 
diverse laboratory parameters and of HE on day 4 
(see Supplementary materials).
Effect of MARS and influence of the ACLF 
grade and treatment intensity on survival in 
patients in whom the presence of ACLF could 
be assessed and graded
Among patients where the presence of ACLF 
could be confirmed (n = 165), there were no sig-
nificant differences in the 30-day (61.5% versus 
63.5%) and 10-day (80.8% versus 86.5%) proba-
bility of survival between patients treated with 
SMC and those treated with MARS (Figure 2(c)). 
Remarkably, reclassification of ACLF patients 
according to treatment intensity indicated again 
that survival was improved in the HIT group com-
pared with the LIT group [(10-day survival: 
97.8% versus 78.6%, p = 0.001; 30-day survival: 
73.3 versus 58.5, p = 0.041); see Figure 2(d)].
Patients with ACLF 1 and ACLF 2 in the HIT 
group showed significantly higher 10-day proba-
bility of survival (p = 0.001) than patients in the 
Figure 2. (a) 30-day survival according to allocation to SMC or MARS. (b) 30-day survival according to 
allocation to LIT or HIT. (c) 30-day survival according to allocation to MARS-SMC or SMC in ACLF patients. (d) 
30-day survival according to allocation to LIT or HIT in ACLF patients.
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LIT group (Figure 3(a) and (b)). Among the 
patients with ACLF 3, those treated with HIT 
also showed a clear trend for a higher 10-day 
(p = 0.10) and a 30-day survival (p = 0.086) com-
pared with those treated with LIT (Figure 3(c)). 
To further account for the reported nonlinear 
effect of ACLF on mortality, we estimated the 
30-day probability of death in LIT, HIT and 
CANONIC patients (Supplementary Figure 2). 
Importantly, the curve corresponding to HIT 
patients was almost significantly shifted to the 
right (p = 0.074) when compared with LIT and 
CANONIC patients when the probability of 
death for patients belonging to HIT or LIT was 
estimated for the different values of the CLIF-C 
ACLF score, indicating that mortality tended to 
be lower in HIT patients for identical values of 
the score.
Survival in ACLF patients included in the 
CANONIC study and contextualization of 
findings in the ACLF patients included in the 
meta-analysis
Overall survival of patients included in the meta-
analysis was similar to the CANONIC patients 
despite the increased ACLF severity in the former 
(Supplementary Table 1). Importantly, the prob-
ability of survival, when analyzed according to 
treatment intensity, was lower in the LIT group 
and higher in the HIT group compared with 
patients in the CANONIC study (10-day sur-
vival: CANONIC 80.5% versus LIT 75.1% versus 
HIT 95.6%; 30-day survival: 66.4% versus 58.5% 
versus 73.3%) (Supplementary Figure 3). 
Variables associated with 30-day survival in 
patients with ACLF
The severity of ACLF, age, MELD score, creati-
nine, number of organ failures, the intensity of 
therapy, and the number of MARS sessions were 
associated with 30-day survival in univariate anal-
ysis (Supplementary Table 2). Due to the rela-
tively high number of patients where ACLF could 
not be evaluated, we performed two different 
models to test the robustness of the association 
between intensity of therapy and survival, adjust-
ing the 30-day survival by the severity of liver dis-
ease as estimated by MELD and by ACLF grade. 
As shown in Supplementary Table 2, the number 
of MARS sessions and also the intensity of treat-
ment were independently associated with survival 
in both models.
The safety profile of MARS
Overall, the proportion of AEs in the MARS 
group and the SMC group was similar (45.7% 
versus 45.6%, p = 1; Table 3). Infection, bleeding, 
and development of severe coagulopathy was the 
most frequent AEs. Infection and severe coagu-
lopathy were similarly distributed, but bleeding 
(of any source and severity) was significantly 
higher in the MARS group (24.1% versus 10.2%, 
p = 0.007). The proportion of deaths related to 
severe AEs, however, was similar in both groups 
(7.5% versus 11.1%; p = 0.482). The incidence of 
AEs was also similar in the LIT and HIT groups. 
Interestingly, the incidence and type of adverse 
effects were also similar in the SMC and MARS 
groups and in the HIT and LIT groups across the 
different ACLF grades (Supplementary Tables 3 
and 4).
Figure 3. 30-day survival according to allocation to 
LIT or HIT: (a) ACLF 1; (b) ACLF 2; (c) ACLF 3.
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Discussion
ACLF has no specific treatment other than the 
management of the associated complications of 
cirrhosis and organ support and is a major world-
wide healthcare problem.1,15–18 Initial investiga-
tions suggested that ALS systems, and MARS, 
in particular, provided clinical benefit, but this 
was not confirmed by subsequent RCTs.7–9 
These later studies, which were performed prior 
to the CANONIC study, showed that MARS 
significantly improved liver, renal, and cerebral 
functions but it did not result in survival benefit. 
The present study was justified for several rea-
sons: Exploring the effect of MARS through an 
individual patient data meta-analysis of patients 
with ACLF defined according to the CANONIC 
study may give essential information for the 
design of future RCTs assessing ALS systems; to 
assess the influence of the severity of ACLF on 
the efficacy of ALS systems; and to assess the 
intensity of MARS treatment as a determinant of 
response and survival in prior studies. 
Importantly, to the best of our knowledge, the 
last two factors have never been explored in prior 
RCTs or meta-analysis.
In all of the 285 patients included in the present 
meta-analysis, we confirmed several results previ-
ously described in the RCTs. First, MARS sig-
nificantly improved serum bilirubin and creatinine 
levels within a short period of time (4 days). 
Second, MARS showed a consistent beneficial 
effect on brain function leading to a reduction in 
the proportion of patients with clinically-signifi-
cant HE. Finally, the beneficial effects of MARS 
were not accompanied by the improvement of 
survival. These observations were also repro-
duced in 165 patients with a confirmed diagnosis 
of ACLF.
Meta-analyses are useful for the proposal of new 
hypotheses. Therefore, we performed a post hoc 
analysis to explore the potential effect of treatment 
intensity. Importantly, the number of MARS ses-
sions was independently associated with survival 
in the multivariate analysis both in the whole 
group of patients and in patients with confirmed 
ACLF. In addition, patients who received a high 
number of sessions (more than four) presented a 
higher survival compared with those who received 
fewer sessions. These findings suggest that the use 
of albumin dialysis may prolong survival if given at 
an appropriate dosage. Interestingly, HIT with 
MARS improved survival independent of the 
severity of the syndrome in patients with con-
firmed ACLF, and was an independent predictor 
of survival in the multivariate analysis.
It is conceivable that the beneficial effect on sur-
vival in the HIT group may result from the fact 
Table 3. Adverse events.
Type of Adverse event SMC
% of cases
MARS
% of cases
p value Low-intensity 
group
% of cases
High-Intensity 
group
% of cases
p value
Infection 13.1 20.4 0.153 17.1 15.9 0.826
Severe coagulopathy 1.8 7.4 0.054 4.6 4.8 0.959
Any bleeding 10.2 24.1 0.007 16.4 19.1 0.646
Respiratory failure 3.7 8.9 0.158 5.9 6.3 0.905
Cardiac failure 0.9 1.8 0.566 1.3 1.6 0.877
Acute pancreatitis 1.8 0.8 0.555 1.3 1.6 0.887
Severe thrombocytopenia 0.8 0 0.314 0.7 0 0.519
Seizures 0 0.8 0.318 0 1.6 0.119
Any adverse event 45.7 45.6 1 43.4 52.1 0.201
Adverse event related death 7.5 11.1 0.482 7.9 12.7 0.271
MARS, Molecular Adsorbent Recirculating System; SMC, standard medical care.
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that patients that remain alive longer can receive 
more MARS sessions. In contrast, our results 
suggest that the discontinuation of MARS treat-
ment was unrelated to early mortality in most 
patients receiving LIT. Additionally, discontinua-
tion of therapy was not related to a higher preva-
lence of adverse effects, because such prevalence 
was similar in the LIT and the HIT groups. Of 
note, the concept by which we defined the two 
groups of patients according to the 'intensity of 
therapy' refers to the absolute sum of effective 
MARS sessions, and it should not be confused 
with frequency or the technical issues of each sin-
gle MARS treatment.
The use of ALS systems in cirrhosis has suffered 
from the negative impact of the lack of positive 
effects on survival obtained in the RELIEF study, 
but the current meta-analysis strongly suggests 
that this concept should be revisited. The 
CANONIC study has shown that ACLF is a het-
erogeneous condition that requires large and 
complex RCTs for treatment assessment. These 
RCTs should be sufficiently powered and should 
include age, etiology of cirrhosis, type of precipi-
tating events, and number and type of organ fail-
ures as relevant covariates. Importantly, our 
meta-analysis suggests that treatment intensity 
should also be considered in the design of future 
clinical trials. Furthermore, two recent studies14,19 
have shown that the probability of survival was 
similar in patients with grade 2–3 ACLF and in 
cirrhotic patients without ACLF undergoing early 
liver transplantation, suggesting that early liver 
transplantation may be indicated for patients with 
ACLF grade 2–3. The short-term improvement 
of survival observed in our meta-analysis in 
patients with ACLF receiving HIT opens the 
potential for the use of MARS in a more intensive 
way as a bridge for early liver transplantation.
The methodological approach based on individ-
ual patient data meta-analysis provides a more 
robust effect estimation and is a major strength of 
the present study. The comparison of characteris-
tics and outcomes with the patients included in 
the CANONIC study gives further relevance to 
the results of the present work. As with all meta-
analyses, however, the generalizability of the 
results to new populations and settings is limited, 
considering that data are based in RCTs with dif-
ferent inclusion and exclusion criteria. Several 
methodological issues should also be mentioned. 
(i) The diagnosis of organ failure was based on 
individual CRFs, but its estimation was retro-
spective and therefore it has risk of bias; in addi-
tion, organ failure could not be properly assessed 
in a considerable proportion of patients due to 
lack of information in the CRF. (ii) We cannot 
completely exclude a publication bias, although 
the comprehensive search we used makes this 
possibility unlikely. (iii) Grading of intensity of 
therapy was adopted post hoc and may have intro-
duced a selection bias, but the independent value 
of the number of sessions observed in the multi-
variate analysis supports the importance of the 
concept. (iv) The main reasons for discontinuing 
MARS therapy could not be obtained in this 
meta-analysis precluding the possibility to char-
acterize the relationship between MARS discon-
tinuation and outcomes. (v) Our results cannot 
be directly extrapolated to other ALS systems. 
Finally, there was one trial that we could not 
obtain individual data information from, but the 
number of patients enrolled in that study was very 
low and it is thus unlikely to change our results.
In conclusion, the results of this new meta-analy-
sis of pooled individual patient data indicated that 
MARS therapy improved liver, renal, and brain 
function in patients with ACLF but it did not 
have an impact on survival. However, a robust 
post hoc analysis suggested that MARS systems 
may have a beneficial effect on short-term sur-
vival in patients with ACLF if given at an appro-
priate dose. The effect of high-intensity MARS 
therapy was independent of other well-known 
prognostic factors such as MELD or the number 
of organ failures. These relevant factors should be 
considered in the design of new trials assessing 
the effect of ALS devices in patients with ACLF.
Conclusion
ACLF is a common complication of cirrhosis 
that severely impacts the natural course of the 
disease.
This individual patient data meta-analysis shows 
that albumin dialysis in patients with ACLF ame-
liorated liver, and renal function improved HE 
but did not significantly impact survival. However, 
a robust post hoc analysis suggests that patients 
who received the appropriate dosage may present 
a better survival. Adequately delivered albumin 
dialysis may have a potential beneficial effect in 
ACLF patients. A suitable dosage should be eval-
uated in future clinical trials.
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